[go: up one dir, main page]

WO2007010975A1 - Utilisation de psicose dans un agent de prevention de l'augmentation du niveau de d-fructose dans le sang - Google Patents

Utilisation de psicose dans un agent de prevention de l'augmentation du niveau de d-fructose dans le sang Download PDF

Info

Publication number
WO2007010975A1
WO2007010975A1 PCT/JP2006/314365 JP2006314365W WO2007010975A1 WO 2007010975 A1 WO2007010975 A1 WO 2007010975A1 JP 2006314365 W JP2006314365 W JP 2006314365W WO 2007010975 A1 WO2007010975 A1 WO 2007010975A1
Authority
WO
WIPO (PCT)
Prior art keywords
psicose
fructose
blood
food
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/314365
Other languages
English (en)
Japanese (ja)
Inventor
Mitsuhiro Nagata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Seiyaku Co Ltd
Kagawa University NUC
Original Assignee
Teikoku Seiyaku Co Ltd
Kagawa University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Seiyaku Co Ltd, Kagawa University NUC filed Critical Teikoku Seiyaku Co Ltd
Publication of WO2007010975A1 publication Critical patent/WO2007010975A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of D-psicose to suppress the increase in blood D-fructose concentration.
  • rare sugars exist in nature, the abundance is extremely small. Rare sugars are divided into aldoses, ketoses and alcohols by chemical structure. Examples of aldoses include D-alose strength. Examples of ketoses include D-psicose strength. Examples of alcohols include aritol. However, since most of these rare sugars have been difficult to obtain because they were not mass-produced in the past, little research has been conducted on their physiological and pharmacological activities. Recently, a large-scale production method using enzymes has been developed by Dr. Imori, et al., Faculty of Agriculture, Kagawa University, and several rare sugars such as D-psicose, D-allose, and aritol have been produced. Go ahead.
  • Non-patent Document 1 suppression of D-Glucose transport in the isolated intestinal tract (Non-patent Document 1), promotion of insulin secretion from rat spleen j8 cell line (Patent Document 1), vascular endothelial cells Suppression of MCP-1 secretion from strains (Patent Document 1), etc., and in vivo experiments, body fat accumulation mitigating action (Non-Patent Document 2), and not becoming energy in vivo (Non-Patent Document 3), etc.
  • Non-Patent Document 1 suppression of D-Glucose transport in the isolated intestinal tract
  • Patent Document 1 promotion of insulin secretion from rat spleen j8 cell line
  • Patent Document 2 vascular endothelial cells Suppression of MCP-1 secretion from strains
  • Non-Patent Document 2 body fat accumulation mitigating action
  • Non-patent document 1 Fiscal 1999 Science and Technology Comprehensive Research Commission Regional Leading Research Research Results Report “Study on the Mechanism of Action of Rare Sugars as Pharmaceuticals” Kagawa Medical University, Masaaki Tokuda, Yoshishi Konishi, Jun Maeda, Heisei 12 years
  • Non-Patent Document 2 Fiscal 1999 Science and Technology Comprehensive Research Commission Regional Leading Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Matsuo Tatsuhiro, Hashiguchi Mineo, 2000
  • Non-Patent Document 3 Fiscal 2000 Science and Technology Comprehensive Research Commission Regional Leading Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Matsuo Tatsuhiro, Hashiguchi Mineo, 2001
  • Patent Document 1 International Publication Number W003 / 097820
  • D-glucose is measured as a blood sugar level, and high blood sugar becomes a problem in cases such as diabetes.
  • D-fructose is known to cause the onset and exacerbation of obesity, hyperlipidemia or diabetes due to sustained high levels in the blood and / or repeated rapid increases in blood levels (Kobe J. Med. Sci. 48, 125-136, 2002, Diabetes Care 24, 1882-188 7, 2001, Am. J. Nutr. 76,911—911, 2002, Am. J. Clin. Nutr. 79, 537—543 , 2004). Therefore, suppressing the excessive rise in the blood concentration of D-fructose is also significant in terms of prevention of lifestyle diseases such as hyperlipidemia or diabetes or prevention of bad habits. Therefore, the present inventor has examined the effect of D-psicose on the increase in blood D-fructose concentration using test animals.
  • the object of the present invention is to improve hyperglycemia and / or hyperlipidemia, and to prevent obesity, diabetes and / or metabolic syndrome symptoms, Compositions, foods, food ingredients, food supplements, beverages, drinking water, pharmaceuticals containing D-psicose and / or its derivatives suitable for people and / or animals in need of disease prevention and / or symptom improvement, Providing raw materials for preparations and feed.
  • the present invention also provides blood D-fructose, which comprises providing D-psicose when ingesting the power of containing D-fructose as part of its structure or a carbohydrate and / or saccharide containing it.
  • the purpose is to provide a method for using D-psicose, which is characterized by being used to suppress the increase in concentration. That is, the present invention relates to a method for improving hyperglycemia and / or hyperlipidemia, preventing obesity, diabetes and / or metabolic syndrome symptoms, preventing onset and / or improving symptoms. For the purpose of provision.
  • D-psicose has an effect of suppressing an increase in blood sugar.
  • the property of suppressing the increase in the blood concentration of both D-glucose and D-fructose, which is related to abnormalities of sugar metabolism or lipid metabolism, is used for the purpose of blood glucose control and is different from other substances. It ’s clarified that it ’s unclear.
  • the gist of the present invention is the following (1) to (5): a yarn and an adult product that suppress an increase in blood D-fructose concentration.
  • a composition containing D-psicose as an active ingredient which suppresses an increase in blood D-fructose concentration when a carbohydrate and / or saccharide containing D-fructose as part of its structure or ingesting it is ingested.
  • composition according to (1) wherein the composition is a composition that suppresses an increase in D glucose concentration simultaneously with an increase in blood D fructose concentration.
  • D-psicose is a mixture of D-psicose and D-fructose (1), (2) Or the composition of (3).
  • composition is in a form in which a sweetener, seasoning, food additive, food material, food / beverage product, health food / beverage product, pharmaceutical and feed force are selected (1), (4) ) Of any composition.
  • the gist of the present invention is the following method of using D-psicose (6) to (10).
  • D-psicose strength D-psicose is an active ingredient, and the yarn has a form selected from the group consisting of sweeteners, seasonings, food additives, food materials, foods and drinks, health foods and drinks, pharmaceuticals and feeds.
  • D-psicose and / or a derivative thereof as an active ingredient D-psicose and / or a derivative thereof, a carbohydrate having and / or containing D-fructose as part of its structure, and / Or a composition that suppresses the increase in blood D-furatose concentration when saccharides are ingested, a composition that has the effect of simultaneously suppressing an increase in blood D-dulose concentration and D fructose concentration, and these Of D-psicose and / or derivatives thereof in the blood when ingesting carbohydrates and / or sugars with D-fructose as part of and / or containing
  • the present invention relates to a carbohydration which contains and / or contains D-fructose as part of its structure. Increased blood D-fructose level when ingesting foods and / or saccharides! / ⁇ is characterized by inhibiting simultaneous increases in blood D-darcose concentration and D-fructose concentration.
  • Patient drinks, drinking water, health drinking water, patient drinking water, medicines, pharmaceutical raw materials, feed, livestock and / or feed for patients can be provided.
  • the present invention relates to an increase in blood D-fructose concentration or blood D-darcose concentration when ingesting carbohydrates and / or sugars containing and / or containing D-fructose as part of its structure. It is possible to provide a method of suppressing the simultaneous increase in fructose concentration.
  • the present invention is directed to humans and / or animals, and exhibits a rapid increase in blood D-fructose concentration when ingesting carbohydrates and / or sugars containing and / or containing D-fructose as part of its structure. It is possible to prevent or treat the onset and progression of lifestyle-related diseases such as obesity, diabetes, and metabolic syndrome, hyperglycemia, hyperglycemia and / or abnormal carbohydrate metabolism such as metabolic syndrome and / or It also relates to compositions, foods, food ingredients, food additives, beverages, drinking water, drugs, pharmaceutical ingredients, and feeds containing D-psicose suitable for humans and / or animals exhibiting abnormal fat metabolism.
  • lifestyle-related diseases such as obesity, diabetes, and metabolic syndrome, hyperglycemia, hyperglycemia and / or abnormal carbohydrate metabolism such as metabolic syndrome and / or It also relates to compositions, foods, food ingredients, food additives, beverages, drinking water, drugs, pharmaceutical ingredients, and feeds containing D-psicose
  • the present invention suppresses a sudden increase in blood D-fructose concentration when a carbohydrate and / or sugar containing D-fructose as part of its structure and / or containing it is ingested. On how to control.
  • D-psicose With regard to D-psicose, in recent years, with the advent of epimerase (see, for example, JP-A-6-125776), for example, it has become possible to produce from D-fructose, which is a monosaccharide abundant in nature, etc. Although it is still expensive, it has become relatively easy to obtain. It was found that by using D-fructose as a raw material, the problem of raw material cost was solved and a hetero-oligosaccharide expected to have a new physiological activity based on D-psicose was obtained. Among monosaccharides, D-psicose is a hexasaccharide having a ketone group as a reducing group.
  • D-psicose is known to have D and L isomers as optical isomers.
  • D-psicose is a known substance but rarely exists in nature, so it is defined as “rare sugar” according to the definition of the International Association of Rare Sugars.
  • Rare sugars can be defined as monosaccharides (aldoses, ketoses and sugar alcohols) that rarely exist in nature. Also in the present invention, it is a rare sugar based on the above definition, and preferably ketose D-psicose. This definition is ambiguous because it is not a definition of sugar structure or properties. That is, there is no definition of an amount such as a rare sugar that is less than a certain amount. However, there are six types of aldoses that are generally abundant in nature: D-glucose, D-galactose, D-mannose, D-ribose, D-xylose, and L-arabinose. Other aldoses are defined as rare sugars. Is done.
  • ketose D-fructose exists, and other ketoses are rare sugars.
  • Other ketoses include D-tagatose, D-sorbose, L-fructose, L-psicose, L-tagatose, and L-sorbose.
  • Sugar alcohol can be produced by reducing monosaccharides, but D-sorbitol is relatively large in nature, but the others are quantitatively small, so these are also rare sugars.
  • the rare sugar D-psicose used in the present invention has been developed as a method for mass production of rare sugars from monosaccharides existing in large quantities in nature. Can be manufactured.
  • D-psicose used in the present invention.
  • a compound obtained by converting the structure of a molecule from a certain starting compound by a chemical reaction is called a derivative of the starting compound.
  • Derivatives of hexose containing D-psicose include its ester, ether, and sugar alcohols. (When monosaccharides are reduced, aldehyde groups and ketone groups become alcohol groups, resulting in the same number of polyhydric alcohols as carbon atoms), and uronic acid (the monosaccharide alcohol group is oxidized.
  • D Psicose is considered to be less toxic to animals, with no reported toxicity to humans.
  • D-Psycose is a sugar with a refreshing sweetness that dissolves in water and is about 60% stronger than sucrose. Its sweetness is refined and refreshing, and there is no discomfort with bitterness and astringency like saccharin. Rather it is similar to the sweetness of fratatose.
  • D Psicose is in harmony with other tastes of various substances such as acidity, salt to taste, astringency, umami, bitterness, etc., for sweetening and taste improvement of ordinary foods and drinks, quality improvement etc. It can be used advantageously. This study revealed that D-psicose also suppressed the increase in blood levels of D-fructose.
  • compositions targeted by the present invention (food, health food, patient food, food material, health food material, patient food material, food additive, health food additive, patient food additive Drinks, health drinks, patient drinks, drinking water, health drinks, patient drinks, pharmaceuticals, pharmaceutical ingredients, feeds, livestock and / or livestock feeds), D-psicose and / or its derivatives Contains any edible and / or medicinal composition.
  • a composition containing D-psicose as an active ingredient is a food additive, food material, food and drink, pharmaceutical product, quasi-drug, and feed force to suppress an increase in blood D-fructose concentration.
  • the food or drink is a functional food, a dietary supplement, or a health food or drink for suppressing an increase in blood D-fructose concentration.
  • the above feed is feed for livestock, poultry and pets to suppress the increase in blood D-fructose concentration.
  • the food material of the composition containing the above-mentioned D psicose as an active ingredient can be used in any form of food, beverage or feed.
  • its content is not particularly limited, but it depends on the degree of intended function, usage mode, usage amount, etc. It can be adjusted as appropriate, for example 0.05 to 100% by mass.
  • the yarn and composition for suppressing an increase in blood D-fructose concentration of the present invention can be used for the human body, other foods and drinks, pharmaceuticals, feeds and external preparations for skin. It can be taken orally or applied to the skin. Can be formulated into oral and parenteral products according to conventional methods and used in various fields such as seasonings, food additives, food ingredients, food and drink, health food and drink, topical skin preparations, pharmaceuticals and feed can do. For example, when blended with food and drink, foods and drinks for treating or preventing diseases for which an increase in blood D-fructose concentration should be suppressed can be provided. It can be expected to be used as health foods, nutritional foods, etc. due to its preventive effects.
  • D-psicose and / or a derivative thereof is usually blended so as to be contained in an amount of 0.1 to 50% by weight in the composition. Preferably it is 1-50 weight%, More preferably, it is 10-30 weight%. However, if the content is low, it is sufficient to increase the intake of the composition. If the content is high, the intake of the composition may be reduced. Therefore, with regard to the blending ratio, it can be used at a blending ratio close to the lower limit for ordinary foods and beverages. When used in pharmaceuticals, tablets and capsules, it can be used at a blending ratio close to the upper limit.
  • the dosage should be determined by the individual's age, weight and symptoms, etc., but in many cases the effective dose is D-psicose per adult It is appropriate to take 1-50g in divided doses before meals, after meals or with meals.
  • the dose of D-psicose and Z or its derivatives is preferably taken as an oral dose of 0.3 to 50 g daily for adults as D-psicose, but may be increased or decreased appropriately depending on age and symptoms. Is possible.
  • the daily blood sugar elevation inhibitor of the present invention may be taken once a day, or divided into 2 or 3 times a day at an appropriate interval, or before, after, or with a meal. preferable.
  • the composition of the present invention When used for food, it is in a form as it is, a form diluted in oil, a milk form meal, or a form to which a carrier generally used in the food industry is added. It may be prepared.
  • the beverage form is a non-alcoholic beverage or an alcoholic beverage.
  • Non-alcoholic beverages include, for example, non-carbonated beverages such as carbonated beverages, fruit juice beverages, and nectar beverages, soft drinks, sports beverages, tea, coffee, cocoa, etc.
  • the form of food can be mentioned.
  • the use form of the composition of the present invention as a food material or food additive for the purpose of improving the abnormal sugar metabolism and / or abnormal lipid metabolism includes powders dissolved in tablets, capsules, beverages, etc.
  • compositions such as granules, semi-solid bodies such as jelly, liquids such as drinking water, and high-concentration solutions used after dilution.
  • the composition of the present invention can be appropriately added to foods to provide health foods or sick foods for the purpose of improving abnormal carbohydrate metabolism and / or abnormal lipid metabolism.
  • vitamins, carbohydrates, pigments, fragrances and the like that are usually added to foods can be appropriately blended.
  • the food can be eaten in any form, liquid or solid. It can be eaten as a soft capsule encapsulated in gelatin.
  • Capsules are made with a gelatin film prepared by, for example, dissolving water in raw gelatin and dissolving plasticizer (glycerin, D-sorbitol, etc.).
  • the drinking water of the present invention contains 1 to 5% by weight of D-psicose and / or a derivative thereof. It is a clear, colorless, odorless and almost tasteless aqueous solution.
  • the amount is preferably 1.5 to 4% by weight, more preferably 2 to 3% by weight. If it is less than 0.1% by weight, the effect of improving abnormal carbohydrate metabolism and / or abnormal lipid metabolism is not sufficient.
  • This drinking water is colorless and transparent and has a faint sweet smell. Therefore, it can be used as drinking water as it is, and it can also be used for cooking rice, cooking, tea, coffee, etc.
  • the drinking water of the present invention By using the drinking water of the present invention in this way for making a daily meal or a luxury product, it is possible to improve an abnormality in carbohydrate metabolism and / or an abnormality in lipid metabolism without particular awareness.
  • the blood D-fructose concentration will not be greatly reduced below the normal value, so that the sugar concentration in the blood can be adjusted more safely. It is considered possible. This will improve the quality of life of people suffering from abnormal carbohydrate and / or lipid metabolism, such as obesity, diabetes and metabolic syndrome.
  • Pastry prdding, jelly, gummy candy, candy, drop, caramel, chewing gum, chocolate, pastry, butter cream, custard cream, cream puff, hot cake, bread, potato chips, french fries, popcorn, biscuits, crackers, pie, Sponge cakes, castella, waffles, cakes, donuts, biscuits, cookies, rice crackers, rice cakes, rice cakes, buns, candy, etc., dried rice cake products (macaroni, pasta), egg products (mayonnaise, cream), beverages Beverages, lactic acid beverages, lactic acid bacteria beverages, concentrated milk beverages, fruit juice beverages, fruitless beverages, fruit beverages, transparent carbonated beverages, carbonated beverages with fruit juice, fruit colored carbonated beverages, luxury products (green tea, tea, instant coffee, cocoa Canned coffee Drinks), dairy products (ice cream, yogurt, coffee milk, butter, butter sauce, cheese, fermented milk, processed milk), pastes (marmalade, jam, flower paste, peanut paste, fruit paste, fruit syrup) ), Meat products (nome,
  • the above-mentioned food and drink can be processed and produced by blending the composition with a raw material for general foods according to a conventional method.
  • the amount of the composition to be added to the food and drink varies depending on the form of the food and is not particularly limited, but it is usually preferably 0.1 to 50% by weight.
  • the food and drink can also be used as functional foods, nutritional supplements or health foods.
  • the form is not particularly limited.
  • Examples of food production include high-nutrient milk proteins, soy protein, egg albumin and other proteins with balanced amino acids, degradation products thereof, and egg white oligopeptides.
  • soybean hydrolyzate a mixture of amino acids alone can be used according to a conventional method. It can also be used in the form of soft capsules and tablets.
  • Examples of dietary supplements or rice cakes are functional foods such as liquid foods, semi-digested nutritional foods, ingredient nutritional foods, drinks containing saccharides, fats, trace elements, vitamins, emulsifiers, fragrances, etc.
  • Examples of processing forms such as agents, capsules, enteral nutrients and the like.
  • foods and drinks such as sports drinks and energy drinks are further supplemented with nutritional additives such as amino acids, vitamins and minerals, sweeteners and spices to improve nutritional balance and flavor.
  • Fragrances, pigments and the like can also be blended.
  • an antioxidant such as tocopherol, L-corsic acid, BHA, rosemary extract and the like can be used in combination according to a conventional method.
  • composition of the present invention can be applied to feed for livestock, poultry and pets.
  • it can be blended in dry dog food, dry cat food, wet dog food, wet cat food, semi-moist dock food, poultry feed, cattle, swine and other livestock feed.
  • the feed itself can be prepared according to a conventional method.
  • These therapeutic and prophylactic agents are non-human animals such as domestic mammals such as cattle, horses, pigs and sheep, poultry such as chickens, quails and ostriches, reptiles, birds or small mammals. It can be used for any pet or farmed fish.
  • the agent of the present invention will be described.
  • the inventor of the present invention is effective in suppressing an increase in blood D-fructose concentration when D-psicose is ingested with carbohydrates and / or sugars containing and / or containing D-fructose as part of its structure.
  • D-psicose and / or a derivative thereof which is used as an active ingredient for the above-mentioned drug for improving the abnormalities of carbohydrate metabolism and / or lipid metabolism, may be used alone or in general shaping.
  • Suitable additives such as powders, stabilizers, preservatives, binders, disintegrants, liquids, granules, fine granules, powders, tablets, capsules, pills, ointments, patches, sprays
  • an appropriate dosage form such as a spray or injection can be selected and formulated and administered orally, nasally, transdermally or intravenously.
  • composition of the present invention in clinical application of the composition of the present invention as a drug, D-psicose and / or a derivative thereof as an active ingredient is used as a solid, semi-solid or liquid pharmaceutical carrier, such as a diluent, an excipient. It is desirable to prepare a preparation containing additives such as an agent and a stabilizer.
  • the ratio of the active ingredient to the carrier component can vary between 1 and 90% by weight.
  • the dosage form and mode of administration are liquids, granules, fine granules, powders, tablets, capsules, pills, ointments, patches, sprays, sprays or injections. Or it may be administered orally with the bulk. When used as a liquid, it may be administered nasally or intravenously in addition to oral administration.
  • a pharmaceutical organic or organic solid, semi-solid or liquid carrier, solubilizer or diluent suitable for oral administration, nasal administration, transdermal administration, or intravenous administration is used as a composition of the present invention. It can be used to prepare as a medicine. Water, gelatin, lactose, starch, magnesium stearate, talc, animal and vegetable oils, benzyl alcohol, gum, polyalkylene glycol, petroleum oil, coconut oil, lanolin, or other carriers used in medicine are All can be used as a carrier for a medicament containing the composition of the present invention.
  • the drug containing the composition of the present invention is effective as another drug that can be appropriately administered together with the drug of the present invention in improving abnormal carbohydrate metabolism and / or abnormal lipid metabolism. It may contain components. In the case of granules, fine granules, capsules, powders, tablets, ointments, patches, sprays or sprays, it is preferable to contain 5 to 80% by weight of the composition of the present invention. In the case of a liquid preparation or injection, the corresponding amount (ratio) is preferably 1 to 80% by weight.
  • the clinical dosage is preferably taken to adults as a daily dose of 1 to 50 g as D-psicose and / or its derivative, but should be increased or decreased as appropriate according to age, symptoms, etc. Is also possible.
  • the daily dose of the agent of the present invention is preferably administered once a day or divided into two or more times at an appropriate interval, or before, after or with a meal.
  • D-psicose and / or its derivatives are used as a raw material for the preparation of other drugs, etc. for the purpose of improving abnormal carbohydrate metabolism and / or abnormal lipid metabolism as pharmaceuticals. It can also be used for preservatives, binders, disintegrants. Alternatively, for example, when a glucose metabolism abnormality and / or lipid metabolism abnormality occur secondaryly, in addition to treating the causative disease, it is necessary to improve the carbohydrate metabolism abnormality and / or lipid metabolism abnormality.
  • the composition of the present invention can also be used as a raw material for the preparation as described above for the production of a therapeutic agent for causative diseases in such cases. In this case, the amount of D-psicose and / or its derivative used and the ratio with other drugs can be appropriately adjusted depending on the content or nature of these therapeutic agents in the preparation.
  • the measured values were expressed as mean values and standard errors, and the significance test was performed using Tukey's multiple range test.
  • the rat blood D-fructose concentration after fasting for 24 hours was about 9 mg / dL.
  • the blood concentration of D-fructose increased 15 minutes after sucrose administration and reached 16.4 mg / mL 30 minutes later. Thereafter, the blood concentration at 30 minutes after administration reached its maximum value, and the blood concentration of D-fructose decreased, and returned to the value before sucrose administration 120 minutes after administration.
  • the blood D-fructose concentration in the D-psicose group continued to decline gradually after 2 hours of administration, and the blood D-fructose concentration was significantly lower than that of D-fructose lg / kg alone after 4 hours of administration. (Fig. 2).
  • D—glucose is measured as a blood sugar level, and high blood sugar becomes a problem when diabetes or the like occurs.
  • D-fructose it is said that obesity, hyperlipidemia, or diabetes develops or worsens when a high concentration in the blood persists (Non-patent document 7, Non-patent document 8).
  • D-psicose and D-fructose belong to ketose, and D-psicose has the potential to suppress D-fructose transport in the intestine more strongly than D-glucose transport, which belongs to aldose. Suggests.
  • D psicose suppresses the increase in the blood concentration of D-fructose as well as D-glucose, resulting in abnormal sugar metabolism or lipid metabolism such as obesity, hyperlipidemia, diabetes or metabolic syndrome. It provides an extremely useful means for preventing lifestyle-related diseases caused by the disease, improving symptoms and / or preventing bad habits.
  • D psicose and / or a derivative thereof exhibits an effect of suppressing an increase in blood D-fructose concentration in experimental animals.
  • D-psicose and / or its derivatives are presumed to have an effect of improving hyperglycemia and / or hyperlipidemia, and sugars such as obesity, hyperlipidemia, diabetes or metabolic syndrome Metabolism! / Provides a new means for preventing and coping with lifestyle-related diseases caused by abnormal lipid metabolism.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention consiste à éviter la progression ou à améliorer une condition d'obésité, de diabètes ou de syndrome métabolique. L'invention concerne une composition contenant du D-psicose et/ou un dérivé de celui-ci en tant que principe actif, qui, lorsqu'un hydrocarbure et/ou un saccharide contenant du D-fructose comme partie de la structure ou contenant du D-fructose est ingéré, peut prévenir l'augmentation dans le sang du niveau de D-fructose, de préférence aussi l'augmentation dans le sang du niveau de D-glucose simultanément. Le D-psicose peut consister en un mélange de D-psicose et de D-fructose. La composition peut être utilisée sous n'importe quelle forme sélectionnée dans le groupe constitué d'un édulcorant, d'un stabilisateur, d'un additif alimentaire, d'une matière alimentaire, d'une boisson/aliment, d'une boisson/aliment sains, d'un produit pharmaceutique et d'une matière première. L'invention concerne également l'utilisation de D-psicose dans la prévention de l'augmentation dans le sang du niveau de D-fructose, de préférence également dans la prévention de l'augmentation dans le sang du niveau de D-glucose simultanément, par administration de D-psicose lorsqu'un hydrocarbure et/ou un saccharide contenant du D-fructose en tant que partie de la structure ou contenant du D-fructose est ingéré.
PCT/JP2006/314365 2005-07-20 2006-07-20 Utilisation de psicose dans un agent de prevention de l'augmentation du niveau de d-fructose dans le sang Ceased WO2007010975A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005209639 2005-07-20
JP2005-209639 2005-07-20
JP2006196752A JP5240810B2 (ja) 2005-07-20 2006-07-19 Ｄ−プシコースの血中ｄ−フラクトース濃度上昇抑制への使用
JP2006-196752 2006-07-19

Publications (1)

Publication Number Publication Date
WO2007010975A1 true WO2007010975A1 (fr) 2007-01-25

Family

ID=37668847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/314365 Ceased WO2007010975A1 (fr) 2005-07-20 2006-07-20 Utilisation de psicose dans un agent de prevention de l'augmentation du niveau de d-fructose dans le sang

Country Status (2)

Country Link
JP (1) JP5240810B2 (fr)
WO (1) WO2007010975A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059625A1 (fr) * 2006-11-17 2008-05-22 National University Corporation Kagawa University Utilisation de la fonction de sucre rare en tant que promoteur de la migration de glucokinase depuis le noyau jusqu'au cytoplasme
US9259022B2 (en) 2013-03-15 2016-02-16 Tate & Lyle Ingredients Americas Llc Sweetener
US9491960B2 (en) 2013-03-15 2016-11-15 Tate & Lyle Ingredients Americas Llc Sweetener
US9854827B2 (en) 2013-03-15 2018-01-02 Tate & Lyle Ingredients Americas Llc Sweetener
JP2019041710A (ja) * 2017-09-05 2019-03-22 香川県 希少糖を配合する鶏用餌
CN110139563A (zh) * 2016-12-26 2019-08-16 Cj第一制糖株式会社 促进植物脂质排泄出体外的包含阿洛酮糖的组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4841617B2 (ja) * 2006-03-03 2011-12-21 株式会社希少糖生産技術研究所 抗線虫用組成物および抗線虫性組成物を用いる線虫制圧法
JP5314207B1 (ja) * 2013-03-14 2013-10-16 株式会社 伊藤園 ミネラル含有飲料及びその製造方法、並びにミネラル含有飲料の塩味抑制方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097820A1 (fr) * 2002-05-22 2003-11-27 Fushimi Pharmaceutical Co.,Ltd. Procede pour utiliser l'activite physiologique d'un saccharide rare et compositions contenant un saccharide rare
JP2005213227A (ja) * 2004-01-30 2005-08-11 Teikoku Seiyaku Co Ltd Ｄ−プシコースの血糖上昇抑制効果の利用
WO2006101118A1 (fr) * 2005-03-23 2006-09-28 National University Corporation Kagawa University Application du d-psicose pour supprimer l’augmentation anormale du rythme circadien de la glycemie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3333969B2 (ja) * 1992-10-08 2002-10-15 株式会社林原生物化学研究所 Ｄ−ケトヘキソース・３−エピメラーゼとその製造方法並びに用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097820A1 (fr) * 2002-05-22 2003-11-27 Fushimi Pharmaceutical Co.,Ltd. Procede pour utiliser l'activite physiologique d'un saccharide rare et compositions contenant un saccharide rare
JP2005213227A (ja) * 2004-01-30 2005-08-11 Teikoku Seiyaku Co Ltd Ｄ−プシコースの血糖上昇抑制効果の利用
WO2006101118A1 (fr) * 2005-03-23 2006-09-28 National University Corporation Kagawa University Application du d-psicose pour supprimer l’augmentation anormale du rythme circadien de la glycemie

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059625A1 (fr) * 2006-11-17 2008-05-22 National University Corporation Kagawa University Utilisation de la fonction de sucre rare en tant que promoteur de la migration de glucokinase depuis le noyau jusqu'au cytoplasme
US9259022B2 (en) 2013-03-15 2016-02-16 Tate & Lyle Ingredients Americas Llc Sweetener
US9491960B2 (en) 2013-03-15 2016-11-15 Tate & Lyle Ingredients Americas Llc Sweetener
US9635879B2 (en) 2013-03-15 2017-05-02 Tate & Lyle Ingredients Americas Llc Sweetener
US9854827B2 (en) 2013-03-15 2018-01-02 Tate & Lyle Ingredients Americas Llc Sweetener
CN110139563A (zh) * 2016-12-26 2019-08-16 Cj第一制糖株式会社 促进植物脂质排泄出体外的包含阿洛酮糖的组合物
US11191285B2 (en) 2016-12-26 2021-12-07 Cj Cheiljedang Corporation Allulose-containing composition for promoting excretion of vegetable lipids from the body
JP2019041710A (ja) * 2017-09-05 2019-03-22 香川県 希少糖を配合する鶏用餌
JP7036361B2 (ja) 2017-09-05 2022-03-15 香川県 希少糖を配合する鶏用餌

Also Published As

Publication number Publication date
JP5240810B2 (ja) 2013-07-17
JP2007051136A (ja) 2007-03-01

Similar Documents

Publication Publication Date Title
JP6581902B2 (ja) エネルギー消費の促進および／またはエネルギー消費機能低下の治療および／または予防剤、または方法
JP5639759B2 (ja) 砂糖様味質をもつ新規甘味料、その製造法および用途
JP5535456B2 (ja) 食物繊維と希少糖を含む生体機能改善組成物。
JP5876205B2 (ja) Ｄ−ソルボースからなる甘味料におけるｄ−ソルボースの甘味の不足や、甘味の持続を改良する方法
KR101974975B1 (ko) 생체 대사 파라미터를 개선하기 위한 조성물
KR20120004492A (ko) 목적으로 하는 헥소오스를 소정량 포함하는, 원료당과는 상이한 당 조성의 당 조성물의 제조 방법 및 제조된 당 조성물의 용도
JP5749880B2 (ja) Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤
JP5645183B2 (ja) Ｄ−プシコースを有効成分として含む肥満状態改善剤
JP5240810B2 (ja) Ｄ−プシコースの血中ｄ−フラクトース濃度上昇抑制への使用
JP4915959B2 (ja) 砂糖様味質をもつ新規甘味料、その製造法および用途
EP3103457A1 (fr) Agent destiné à maintenir la satiété et procédé servant à maintenir la sensation de rassasiement
JP6391959B2 (ja) 非アルコール性脂肪性肝炎の改善剤および改善用栄養組成物
JP5943516B2 (ja) Ｄ−ソルボースを有効成分とする生体機能改善用甘味料
JPWO2008123417A1 (ja) 抗疲労剤
JP7156639B2 (ja) レスベラトロール誘導体の新規用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06781325

Country of ref document: EP

Kind code of ref document: A1